相关实验视频
Updated: Dec 29, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
981
癌症免疫疗法的新辅助检查点封锁
Suzanne L Topalian1,2, Janis M Taube2,3, Drew M Pardoll2,4
1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. stopali1@jhmi.edu.
概括
在手术前使用抗PD-1/PD-L1药物的新辅助免疫疗法有望克服癌症治疗耐药性. 研究探讨了提高癌症早期疗效的机制和试验设计.
科学领域:
- 癌症学
- 免疫学
- 癌症研究
背景情况:
- 编程细胞死亡1 (PD-1): 编程死亡1 (PD-L1) 途径抑制剂已经彻底改变了癌症治疗.
- 尽管具有广泛的疗效,但许多晚期瘤对当前免疫疗法产生抵抗力.
- 研究早期的治疗干预措施对于改善患者的结果至关重要.
研究的目的:
- 审查针对PD-1途径的新辅助 (手术前) 免疫治疗的发展.
- 突出生物机制,临床试验设计和新辅助环境中的病理反应评估的关键考虑因素.
- 通过新的组合来确定增强抗PD-1/抗PD-L1功效的策略.
主要方法:
- 在PD-1通路阻塞的背景下对新辅助免疫疗法的文献综述.
- 对新辅助免疫疗法的反应和耐药性的生物学机制的分析.
- 对新辅助免疫治疗的临床试验设计和病理评估方法的检查.
主要成果:
- 新辅助免疫疗法是克服各种癌症治疗耐药性的有希望的策略.
- 在瘤进展之前,PD-1/ PD- L1阻塞的早期应用可能会增强抗瘤免疫力.
- 评估病理反应对于评估治疗疗效和指导未来研究至关重要.
结论:
- 新辅助免疫疗法具有显著的改善癌症治疗疗效的潜力.
- 需要进一步研究生物机制和最佳试验设计.
- 这些发现可能有助于开发组合疗法,以提高抗PD-1/抗PD-L1的有效性.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines
882
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
882
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K

